Chronic Obstructive Pulmonary Disease (COPD) is a long-term lung disease that makes it hard for people to breathe. The main symptoms are shortness of breath, wheezing, fatigue, coughing, and mucus production. People with COPD experience episodes of acute exacerbations and continuous lung function decline.
Proteins involved in COPD’s inflammatory pathway contribute to making people unwell. The study medication in this trial blocks the actions of the proteins, inhibiting the inflammatory pathway. It may be effective in preventing acute moderate and severe COPD exacerbations and improving lung function and quality of life. The study medication is used in addition to people’s existing medication.
You may be eligible to take part in a clinical trial of the study medication if you:
- Are aged between 40 and 80 years old
- Have a history (at least one year) of living with poorly controlled COPD
- Use three different types of inhalers including a steroid and have had at least two moderate exacerbations in a year requiring steroids and/or antibiotics OR one severe exacerbation requiring hospitalisation or an Emergency Department visit lasting more than 24 hours.
If you answered YES to these questions and would like to learn more, please contact us for more information about the trial and possible participation.
